farnesol has been researched along with Leukemia, Promyelocytic, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katagiri, T; Kizaki, M; Miyazawa, K; Nishimaki, J; Tohyama, K; Toyama, K; Yaguchi, M | 1 |
| Doe, M; Hamada, M; Nishio, K; Tanaka, T; Usuki, Y | 1 |
2 other study(ies) available for farnesol and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid.
Topics: Apoptosis; Bone Marrow; Diterpenes; Drug Synergism; Farnesol; Flow Cytometry; Gefarnate; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Molecular Structure; Myelodysplastic Syndromes; Structure-Activity Relationship; Tretinoin; Tumor Cells, Cultured; Vitamin K; Vitamin K 1; Vitamin K 2 | 1997 |
Farnesylpyridinium, an analog of isoprenoid farnesol, induces apoptosis but suppresses apoptotic body formation in human promyelocytic leukemia cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Cysteine Proteinase Inhibitors; Cytochalasin B; DNA; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Farnesol; HL-60 Cells; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Mitochondria; Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors; Pyridinium Compounds; Sesquiterpenes | 2002 |